

Val Delp

Counsel

Philadelphia

Biography

Val helps public companies tackle a broad range of complex securities and corporate matters impacting day-to-day and strategic operations.

Public companies rely on Val to help them navigate the ever-evolving landscape of SEC reporting, securities law compliance and corporate governance. She advises management and boards of directors on SEC disclosure obligations, compliance with NYSE and Nasdaq rules, and shareholder engagement and activism. Val also has a proven record of effectively counseling clients on securities and corporate issues in a range of transactions, including mergers, acquisitions, spin-offs, public and private offerings, restructurings and global reorganizations.

Val maintains a diverse pro bono practice, including representing asylum seekers and assisting nonprofits with governance issues.

Before joining Hogan Lovells, Val worked in the Washington, D.C. office of another leading international law firm where she advised clients on a range of corporate and securities matters.

Prior to practicing law, Val worked in both the U.S. Senate and U.S. House of Representatives and spent several election cycles developing and implementing fundraising strategies on political campaigns.

Representative experience

Sesen Bio (NASDAQ:SESN), a clinical stage



Phone

+1 267 675 4649

Fax

+1 267 675 4601

Email

val.delp@hoganlovells.com

Practices

Capital Markets

Corporate Governance and
Public Company Representation

Mergers and Acquisitions

Securities and Public Company
Advisory

Industries

Consumer

Life Sciences and Health Care

Areas of focus

Carve-outs, Spin-offs, and Split-offs

Raising Equity Capital

biopharmaceutical company, on its reverse merger with Carisma Therapeutics, a biopharmaceutical company focusing on cellular immunotherapy.

Urstadt Biddle Properties Inc. (NYSE:UBP) on its sale to Regency Centers Corporation in an all-stock transaction valued at US\$1.4B.

Conformis, Inc. (NASDAQ:CFMS) on its sale to restor3d, Inc. in an all-cash transaction.

Marvell Technology Group (NASDAQ:MRVL) on its US\$10bn acquisition of Inphi (NYSE: IPHI) in a cash-and-stock transaction.

Rosetta Stone (NYSE:RST) on its US\$792m sale to Cambium Learning Group in an all-cash transaction.

Dialog Semiconductor (XETRA:DLG) in its US\$500m acquisition of Adesto Technologies (NASDAQ: IOTS).

A clinical-stage pharmaceutical company in various at-the-market equity offerings led by Jefferies.

A commercial-stage pharmaceutical company in its US\$46m follow-on public offering of common stock led by Piper Sandler and Cantor.

A clinical-stage pharmaceutical company in a registered direct offering and concurrent private placement.

A worldwide leader in automotive safety during an internal reorganization and spin-off of its active safety technology business into a new publicly traded company.*

A privately held global producer of audio products, electronics, and software in a cross-border reorganization.*

*Matter handled prior to joining Hogan Lovells.

Latest thinking and events

- News
 - SEC staff expands availability of nonpublic registration statement review process
- News
 - SEC staff revives former guidance on

Disclosure and Reporting Obligations

Governance

Public Company Mergers and Acquisitions

Stock Exchange Listings and Regulatory Compliance

Proxy Solicitations, Shareholder Meetings, and Shareholder Proposals

Section 16 Advice

Education and admissions

Education

J.D., American University
Washington College of Law,
2014

B.A., Emory University, 2008

Bar admissions and qualifications

Pennsylvania

District of Columbia

shareholder proposals raising social policy issues

- News

- SEC enforcement targets beneficial ownership reporting violations

- News

- SEC brings Regulation FD enforcement action for selective disclosure via social media

- News

- Mandatory compliance nears for remaining Section 13 reporting requirements

- Press releases

- Hogan Lovells Guides Mind Medicine Inc. on its US\$75m Underwritten Public Offering